ArticleVeterinary surgery : VS2026
Clinically relevant intra-articular corticosteroid doses impair equine osteoclast function in vitro.
Article in Veterinary surgery : VS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinically relevant intra-articular corticosteroid doses impair equine osteoclast function in vitro.Veterinary surgery : VS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo assess the effects of clinically relevant doses of commonly employed intra-articular corticosteroids-specifically, triamcinolone acetonide (TCA), methylprednisolone acetate (MPA), and combination of betamethasone acetate and betamethasone sodium phosphate (BM)-on equine osteoclasts. STUDY
designIn vitro controlled laboratory study. SAMPLE POPULATION: Three donor mares (13-19 years).
methodsFollowing differentiation from bone marrow aspirates, osteoclasts were cultured alone (pure osteoclast cultures; n = 18 wells per group) or on equine bone slices (osteoclast-bone cultures; n = 6 wells per group) and treated with TCA (36 μg/mL), MPA (48 μg/mL), or BM (4 μg/mL). Untreated wells were controls. Outcome parameters included number of osteoclasts, bone resorption area and media biomarker concentrations, specifically tartrate-resistant acid phosphatase isoform-5b (TRACP-5b) and C-terminal telopeptide of type I collagen (CTX-I), measured using enzyme-linked immunosorbent assay (ELISA).
resultsIn pure osteoclast cultures (n = 16 wells in control and BM groups; n = 17 wells in TCA and MPA groups), mature osteoclast numbers were lower following corticosteroid addition compared with controls (MPA, p < .001; TCA, p = .009; BM, p = .002), and lower in the MPA group than the TCA group (p = .015). There was no difference in TRACP-5b between groups. In osteoclast-bone cultures (n = 5 in control group; n = 6 wells in TCA, MPA and BM groups), CTX-I decreased with MPA treatment compared with controls (p = .001), TCA (p = .006), and BM (p = .007) groups. TRACP-5b decreased with TCA compared with controls (p = .001). No differences in bone resorption area were measured.
conclusionClinically relevant doses of commonly employed intra-articular corticosteroids-TCA, MPA, and BM-impacted equine osteoclast activity in vitro. CLINICAL SIGNIFICANCE: Understanding that intra-articular corticosteroids may influence osteoclast activity, potentially affecting subchondral bone remodeling and repair, is important for guiding judicious use in equine joint management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.